CHDI Selects Amphora Discovery's Integrated Discovery Services …

     CHDI Selects Amphora Discovery's Integrated Discovery Services
                  in Pursuit of Huntington Disease Cure
Research Triangle Park, NC, and Los Angeles, CA, September 18th ­ Amphora
Discovery announced today that CHDI, Inc., a non-profit organization pursuing a biotech
approach to rapidly discover and develop drugs that prevent or slow Huntington Disease
(HD) has signed multiple agreements that provide access to Amphora Discovery's integrated
contract discovery services. HD is an inherited degenerative brain disease for which there is
currently no treatment to delay or prevent its onset. CHDI partners with leading industrial
and academic institutions to discover novel therapies for HD and will utilize Amphora
Discovery's services and expertise in drug discovery to further this mission.

The agreements cover multiple biological targets implicated in HD and include access to
Amphora Discovery's PrecisionScreenTM, PrecisionSelectTM and Full Hit-to-Lead services.
Utilizing its highly precise and accurate PrecisionScreenTM technology, Amphora Discovery
will rapidly screen a large number of CHDI compounds against the implicated proteins in
parallel. The high quality of the PrecisionScreenTM data, combined with the parallel
screening of the targets, will enable the primary data to be used for direct Structure Activity
Relationship (SAR) mining. This unique Amphora Discovery service avoids lengthy retest
times and will enable CHDI to rapidly select and prioritize the best chemical series for
further development. Amphora Discovery will then use its powerful PrecisionSelectTM
selectivity profiling platform to further characterize the compounds of interest. Finally,
CHDI and Amphora Discovery will initiate a Full Hit-to-Lead program to rapidly structurally
optimize multiple chemical series against all the implicated targets in parallel.

"Amphora Discovery is a highly experienced drug discovery partner with a validated process
that delivers high quality data on reduced timelines. CHDI's mission is to support projects
that hold specific potential for discovery and development of practical therapeutics ready for
preclinical testing within a three to five year timeframe. We believe that Amphora
Discovery's optimized drug discovery process provides us with the ability to achieve this
goal," said Dr. Robert Pacifici, Chief Scientific Adviser to CHDI.

"We are very pleased that CHDI has selected Amphora Discovery as a preferred partner.
Amphora Discovery's PrecisionScreenTM, PrecisionSelectTM and Full Hit-to-Lead services
provide our customers with an integrated solution to drug discovery. Since our inception we
have performed more than 100 high throughput screening campaigns and generated over 35
million data points with our validated technology platform. We look forward to using our
platform and expertise to assist CHDI in their fight against HD," said Bill Janzen, Founder
and Chief Technology Officer at Amphora Discovery.
About Huntington Disease (HD)
HD is a familial disease, passed from parent to child through a mutation in a gene. Each child of an
HD parent has a 50-50 chance of inheriting the HD gene which causes programmed degeneration of
brain cells and results in emotional disturbance, loss of intellectual faculties and uncontrolled
movements. Most people with HD develop the symptoms at midlife but in some people onset occurs
in infancy or old age. The average survival time after onset is approximately fifteen to twenty years. It
is estimated that about one in every 10,000 persons has the HD gene. At this time, there is no way to
stop or reverse the course of HD.


About CHDI, Inc. and High Q Foundation
CHDI Inc. and the High Q Foundation, Inc. (High Q) are non-profit organizations that share the
mission of bringing together academia, industry, governmental agencies, and other funding
organizations in the search for Huntington disease (HD) treatments.

CHDI, Inc. is pursuing a biotech approach to rapidly discover and develop drugs that prevent or slow
HD. Through collaborations with industrial and academic partners, CHDI, Inc., participates in all
aspects of drug discovery and development from high throughput screening to preclinical
development. For more information about CHDI, Inc. and its collaborative programs please see
www.chdi-inc.org or contact Robert Pacifici (robert.pacifici@chdi-inc.org).

High Q supports HD research aimed at target identification and validation, the development and use
of animal models, drug delivery, and the search for markers of disease progression. For more
information about High Q and its support of HD research please see www.highqfoundation.org or
contact      Ethan    Signer       (ethan.signer@highqfoundation.org)       or     Allan     Tobin
(allan.tobin@highqfoundation.org).



About Amphora Discovery Corp.
Amphora Discovery Corporation is a leading biotechnology company, with two dedicated business
units. The Amphora Pharma Business Unit is focused on development and out-licensing of the
company's broad selection of high-value lead candidates. The Amphora Discovery Business Unit is a
leading provider of integrated contract services for the pharmaceutical industry, employing cutting-
edge chemogenomic, systems biology and microfluidics technologies to deliver innovative and
targeted lead generation and lead optimization solutions.
For further information about Amphora Discovery contact:
Bill Janzen                                 Julian Abery
Chief Technology Officer & co-Founder       Executive Director, Corporate Development
Amphora Discovery Corporation               Amphora Discovery Corporation
Phone: 919-287-6266                         Phone : 919-287-6174
Email: bill.janzen@amphoracorp.com          Email : julian.abery@amphoracorp.com
www.amphoracorp.com